An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain.
Wu, N.C., Yuan, M., Liu, H., Lee, C.D., Zhu, X., Bangaru, S., Torres, J.L., Caniels, T.G., Brouwer, P.J.M., van Gils, M.J., Sanders, R.W., Ward, A.B., Wilson, I.A.(2020) Cell Rep 33: 108274-108274
- PubMed: 33027617 
- DOI: 10.1016/j.celrep.2020.108274
- Primary Citation of Related Structures:  
7JMO, 7JMP - PubMed Abstract: 
IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 because of structural constraints in binding the RBD (mode A) ...